Lei Jianping on April 9
Shenzhen Akcome Biotechnology Co., Ltd. (hereinafter referred to as "iKang Biotech") IPO was terminated a few days ago, and iKang Biotech was preparing to be listed on the Science and Technology Innovation Board.
iKang Biotech originally planned to raise 600 million yuan, of which 256 million yuan was used for the construction project of iKang Biological Industrial Base, 178 million yuan was used for the construction project of Aikang Biotechnology R&D Center, and 166 million yuan was used to supplement working capital.
Annual revenue of 400 million
Founded in 2003, AKCOME Biotech is an enterprise specializing in the research and development of medical equipment and in vitro diagnostic reagent products, integrating production, sales and after-sales service.
Akcome Biotech has four platform products: enzyme immunization, blood grouping, chemiluminescence and POCT, and is committed to providing high-quality products and professional services for hospitals, blood banks and other clinical testing institutions.
According to the prospectus, the revenue of Akcome Biotech in 2019, 2020 and 2021 will be 239 million yuan, 370 million yuan and 397 million yuan respectively, the net profit will be 31.12 million yuan, 74.8338 million yuan and 55.948 million yuan respectively, and the net profit after deducting non-profits will be 29.38 million yuan, 72.0484 million yuan and 52.957 million yuan respectively.
In the first quarter of 2022, Akcome Biotech's revenue was 101 million yuan, with a net profit of 17.22 million yuan, and a net profit of 16.32 million yuan after deducting non-profits.
During the reporting period, the revenue of iKang Bio's enzyme immunoassay products was 101 million yuan, 151 million yuan, 127 million yuan and 25.4577 million yuan respectively, accounting for 42.34%, 40.97%, 31.92% and 25.14% of the main business income respectively, which is one of the main business products and main sources of income of iKang Biotech.
Zhang Chuanguo controls 55% of the shares
The controlling shareholder and actual controller of AKCOME Biotech is Zhang Chuanguo.
Before the IPO, Zhang Chuanguo, chairman of the company, directly held 52.8% of the shares of iKang Biotech, and indirectly held 2.28% of the shares through Bonast Investment, holding a total of 55.08% of the shares of iKang Biotech.
Zhang Chuanguo, born in 1963, graduated from Peking University with a bachelor's degree in German language and literature. From August 1984 to June 1998, he served as a teacher in Wuhan Institute of Water Transport Engineering, from September 1998 to April 2003, he worked for Beijing Sailer Medical Equipment Co., Ltd., from May 2003 to November 2021, he successively served as the general manager and executive director of iKang Co., Ltd., and since December 2021, he has served as the chairman of iKang Biotech.
Qiang Yongping, director and general manager of the company, directly holds 19.20% of the equity, indirectly holds 0.83% of the equity through Bonast Investment, and indirectly holds 0.22% of the equity through Yourenas Investment, holding a total of 20.25% of the shares of iKang Biotech.
Ding Qi, the sales consultant, directly holds 13.40% of the shares, and indirectly holds 0.62% of the shares through Bonast Investment, holding a total of 14.02% of the shares.
In addition, Bonast Investment holds 9.8% of the shares, Small and Medium-sized Venture Capital and Hua Mao Industrial hold 1% of the shares respectively, Urenas Investment holds 0.72% of the shares, and Jiuxiang Investment holds 0.63% of the shares;
Aijie Investment holds 0.48%, Oceanus Investment holds 0.4%, Changsheng Investment holds 0.37%, and Master Investment holds 0.21%.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.